AstraZeneca's Covid-19 vaccine is 76% effective against symptomatic cases, the British-Swedish laboratory announced on Thursday, March 25, after an update of its data from a clinical trial in the States United, Peru, and Chile.
Read also: AstraZeneca: 29 million doses of vaccine found in Italy, Brussels asks for explanations
AstraZeneca pledged Tuesday to provide recent data within 48 hours to the US regulator overseeing clinical trials, which criticized potentially
“obsolete” data
on its anti-Covid vaccine, then announced 79% effective in preventing symptomatic cases.
